Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips

Abstract

BackgroundThe diagnosis rate of early stage esophageal squamous cell carcinoma (ESCC) is low due to the lack of specific tumor markers. Seeking for these markers is beneficial to improve the early diagnosis rate and the prognosis of patients. This study profiles the differentially expressed proteins of early stage ESCC patients via the AAH-BLG-507 protein chip, which further consolidates the clinical evidence of ESCC diagnosis.Materials and methodsIn this study, 20 serum samples were collected from Taihe Hospital between August 2016 and June 2017. Ten of them carried ESCC, while the rest were healthy controls. To profile the proteins’ expression level, the AAH-BLG-507 protein chip was used, and both highly expressed and lowly expressed proteins were fished out. Meanwhile, their biological roles were examined by using Gene Ontology (GO) database and String database, and they were further verified by ELISA.ResultsResults showed that the expression levels of AXL, ARTN, Ang2, BDNF, BMP7, cripto-1, CCL28, E-selectin, IL-6, IL-8 and SHH in the serum of early ESCC were significantly upregulated (P<0.05), particularly IL-6 and IL-8. The expression levels of TSP1 and MMP-8 were markedly downregulated (P<0.05). Analysis showed that these proteins were mainly involved in angiogenesis, signal transduction, cell proliferation and migration, indicating the close relationship with the development of ESCC.ConclusionIt suggested that IL-6 and IL-8 proteins could be considered as the markers for ESCC diagnosis.

Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas

“…On the contrast, Łukaszewicz-Zając et al found a stronger predictive value of IL-6 as compared to carcinoembryonic antigen (CEA) levels in EAC patients without chemotherapy [17]. This is in line with data obtained from ESCCs and other gastrointestinal malignancies indicating an association with increased tumor stage and poor prognosis [8][9][10][11][12][13]. In summary, our data support the role of systemic IL-6 levels as potential biomarker in patients with EACs although a distinct stratification for clinicopathological values or an association with overall survival was not found.…”

“…Proinflammatory cytokines like interleukin-(IL-) 6 or IL-2 mainly attract and activate other inflammatory cells in the tumor microenvironment [5][6][7]. Both interleukins have been reported to play a role in esophageal squamous cell carcinomas (ESCC) and other gastrointestinal malignancies like gastric cancers [8][9][10][11][12][13][14][15]. However in EACs conflicting results have been reported [16][17][18].…”

Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat

“…2017), which could reverse the changes of cytochrome P450 enzyme activity, and ultrastructure in rats induced by CCl 4 , showing a strong liver preservation effect (Wang et al. 2018) through its antioxidant activities. Although several pharmacological activities of anthraquinones have been reported (He et al.…”

<p>Serum pepsinogen assay is not recommended for the diagnosis of esophageal squamous cell carcinoma: a systematic review and meta-analysis</p>

“…In China, the current diagnosis rate of early EC is low, and EC-specific markers are lacking. Furthermore, our previous study found that serum IL-6 and IL-8 may be an effective indicator for the early diagnosis of ESCC, but the clinical application needs further investigation 6…”